Target intelligence / Profile preview

Plexin-D1 receptor (PLXND1)

Target
PLXND1
Molecular classification
Receptor, Transmembrane protein, Semaphorin receptor
01

Overview

Plexin-D1 receptor (PLXND1) is a single-pass transmembrane receptor belonging to the plexin family and is the sole member of the vertebrate-specific PlexinD subfamily. It serves primarily as a high-affinity receptor for class III semaphorins, especially Semaphorin 3E, and mediates a variety of signal transduction events crucial for embryonic development, including guidance of axons, vascular patterning, regulation of immune cell migration, and skeletal morphogenesis. Its intracellular domain features GTPase-activating (RasGAP) motifs, allowing direct interaction with, and regulation of, small GTP-binding proteins. Plexin-D1 signaling is implicated in cancer progression, particularly due to its overexpression in tumor vasculature and malignant cells, making it a target and potential biomarker for diagnosis and therapy. It also interacts functionally with adaptor proteins such as GIPC and participates in protein complexes involved in endocytosis and cytoskeletal rearrangement[1][2][3][4].

Other names
Plexin D1PlxnD1PLXND1Plexin domain-containing protein 1
02

Mechanism of action

Blocking or modulating semaphorin pathway signaling; Inhibition or alteration of receptor-ligand interactions (notably Sema3E–Plexin-D1); Modulation of downstream Ras GTPase-activating protein (RasGAP) activity[1][3][4].

03

Biological functions

Signal transductionRegulation of cell migrationRegulation of cell proliferationRegulation of cell survivalAxon guidanceRegulation of angiogenesisImmune cell regulation
04

Disease associations

CancerCardiovascular disease (congenital heart defects, vascular malformation)Neurodevelopmental and nervous system disordersBone and skeletal disorders
05

Safety considerations

Possible impact on vascular development with systemic inhibitionPotential interference with normal cardiovascular, nervous, or immune system functions due2 to broad developmental role[1][4].
06

Interacting drugs

None currently approved or in late-stage clinical use known; research compounds and antibodies in preclinical/early clinical development as diagnostic or therapeutic agents[4].
07

Biomarkers

Overexpression in tumor endothelium and malignant cells (diagnostic marker in certain cancers)Expression pattern in developing blood vessels and various tissues[4].

Beyond the preview

Go deeper on Plexin-D1 receptor (PLXND1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plexin-D1 receptor (PLXND1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call